Article Information
History
- September 21, 2021.
Article Versions
- Version 1 (October 21, 2020 - 00:43).
- Version 2 (August 4, 2021 - 09:55).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- 1Department of Oncology, the 900th Hospital of Joint Logistic Support Force, PLA, Fuzong Clinical College of Fujian Medical University, 350025, Fuzhou, Fujian, PR China
- 2Fujian Center for Safety Evaluation of New Drug, Fujian Medical University,350122, Fuzhou, Fujian, PR China
- 3Department of Hepatobiliary Disease, the 900th Hospital of Joint Logistic Support Force, PLA, Fuzong Clinical College of Fujian Medical University, 350025, Fuzhou, Fujian, PR China
- ↵*Correspondence Author: Xiong Chen, Department of Oncology, the 900th Hospital of Joint Logistic Support Force, PLA, Fuzong Clinical College of Fujian Medical University, 156 Xierhuan Northern Road, Fuzhou, 350025, Fujian, P.R.China, Phone: +0086-591-83787037; Fax: 0086-591-24937089; E-mail: cxiongzpc{at}fjmu.edu.cn